Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 485

1.

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.

Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.

Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. Review.

3.

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Nuijten MJ, Wittenberg W, Lebmeier M.

Pharmacoeconomics. 2007;25(1):55-71.

PMID:
17192118
4.

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Review.

PMID:
23633336
5.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660
6.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
7.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
8.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Hampp C, Kauf TL, Saidi AS, Winterstein AG.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.

PMID:
21300647
9.

Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.

Prescott WA Jr, Doloresco F, Brown J, Paladino JA.

Pharmacoeconomics. 2010;28(4):279-93. doi: 10.2165/11531860-000000000-00000. Review.

PMID:
20131925
10.

Cost effectiveness of palivizumab in Spain: an analysis using observational data.

Nuijten MJ, Wittenberg W.

Eur J Health Econ. 2010 Feb;11(1):105-15. doi: 10.1007/s10198-009-0206-x. Epub 2009 Dec 5.

11.

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.

Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.

PMID:
21960187
12.

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.

Eur J Pediatr. 2003 Apr;162(4):237-44. Epub 2003 Feb 6.

PMID:
12647196
13.

Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.

Neovius K, Buesch K, Sandström K, Neovius M.

Acta Paediatr. 2011 Oct;100(10):1306-14. doi: 10.1111/j.1651-2227.2011.02309.x. Epub 2011 May 13.

PMID:
21477089
14.

[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].

Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K.

An Pediatr (Barc). 2006 Oct;65(4):316-24. Spanish.

15.

Health economics and RSV.

Carbonell-Estrany X, Lázaro y de Mercado P.

Paediatr Respir Rev. 2009 Jun;10 Suppl 1:12-3. doi: 10.1016/S1526-0542(09)70006-5. Review.

PMID:
19651392
16.

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.

Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.

Pediatrics. 1999 Sep;104(3 Pt 1):419-27.

PMID:
10469764
17.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
18.

Prevention of respiratory syncytial virus infection with palivizumab.

Thomas M, Bedford-Russell A, Sharland M.

Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8. Review.

PMID:
11057088
19.
20.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.

PMID:
14654627
Items per page

Supplemental Content

Write to the Help Desk